Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc.verified

ITCI

Price:

$73.54

Market Cap:

$7.77B

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treat...[Read more]

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

2014-01-07

Stock Exchange

NASDAQ

Ticker

ITCI

The PE Ratio as of September 2024 (TTM) for Intra-Cellular Therapies, Inc. (ITCI) is -85.51

According to Intra-Cellular Therapies, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -85.51. This represents a change of 3.94% compared to the average of -82.27 of the last 4 quarters.

Intra-Cellular Therapies, Inc. (ITCI) Historical PE Ratio (quarterly & annually)

How has ITCI PE Ratio performed in the past?

The mean historical PE Ratio of Intra-Cellular Therapies, Inc. over the last ten years is -15.77. The current -85.51 PE Ratio has changed 54.14% with respect to the historical average. Over the past ten years (40 quarters), ITCI's PE Ratio was at its highest in in the September 2019 quarter at -2.96. The PE Ratio was at its lowest in in the June 2024 quarter at -108.69.

Quarterly (TTM)
Annual

Average

-15.77

Median

-13.89

Minimum

-49.16

Maximum

-4.02

Intra-Cellular Therapies, Inc. (ITCI) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Intra-Cellular Therapies, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 219.10%

Maximum Annual PE Ratio = -4.02

Minimum Annual Increase = -69.68%

Minimum Annual PE Ratio = -49.16

Quarterly (TTM)
Annual
YearPE RatioChange
2023-49.16153.14%
2022-19.4229.76%
2021-14.9751.85%
2020-9.86-23.10%
2019-12.82219.10%
2018-4.02-41.27%
2017-6.8422.04%
2016-5.60-69.68%
2015-18.4812.19%
2014-16.4871.35%

Intra-Cellular Therapies, Inc. (ITCI) Average PE Ratio

How has ITCI PE Ratio performed in the past?

The current PE Ratio of Intra-Cellular Therapies, Inc. (ITCI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-27.85

5-year avg

-21.25

10-year avg

-15.77

Intra-Cellular Therapies, Inc. (ITCI) PE Ratio vs. Peers

How is ITCI’s PE Ratio compared to its peers?

Intra-Cellular Therapies, Inc.’s PE Ratio is less than Alkermes plc (15.66), less than Ironwood Pharmaceuticals, Inc. (77.85), less than Deciphera Pharmaceuticals, Inc. (-11.74), less than Pacira BioSciences, Inc. (10.06), less than Collegium Pharmaceutical, Inc. (12.07), less than Eagle Pharmaceuticals, Inc. (5.10), less than Neurocrine Biosciences, Inc. (35.71), less than Dynavax Technologies Corporation (84.07), less than Amphastar Pharmaceuticals, Inc. (13.33), less than ANI Pharmaceuticals, Inc. (43.28), less than Cyclo Therapeutics, Inc. (-0.94), less than Amneal Pharmaceuticals, Inc. (-14.85), less than Aquestive Therapeutics, Inc. (-14.78),

Build a custom stock screener for Intra-Cellular Therapies, Inc. (ITCI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Intra-Cellular Therapies, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Intra-Cellular Therapies, Inc. (ITCI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Intra-Cellular Therapies, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Intra-Cellular Therapies, Inc.'s PE Ratio?

How is the PE Ratio calculated for Intra-Cellular Therapies, Inc. (ITCI)?

What is the highest PE Ratio for Intra-Cellular Therapies, Inc. (ITCI)?

What is the 3-year average PE Ratio for Intra-Cellular Therapies, Inc. (ITCI)?

What is the 5-year average PE Ratio for Intra-Cellular Therapies, Inc. (ITCI)?

How does the current PE Ratio for Intra-Cellular Therapies, Inc. (ITCI) compare to its historical average?